One of the original players in the development of Amgen's cancer therapy talimogene laherparepvec (T-Vec), now up under review at the FDA, has started a new biotech focused on oncolytics drug development. And the U.K. company attracted a $30 million startup round from a transatlantic group of venture players to get started with a splash.